Janssen Pharmaceutica and Proteros expand relationship and enter into global agreement
MARTINSRIED, Germany—Janssen Research &Development, a division of Janssen Pharmaceutica NV and Proterosbiostructures GmbH recently announced they have entered into along-term global service agreement granting Janssen privileged access toProteros portfolio of discovery technologies and services.
Under the agreement Janssen will have broad accessto Proteros' drug discovery technologies, including structural biology,biophysical screening and profiling service, novel fragment libraries,medicinal chemistry expertise and fully integrated structure-based leaddiscovery programs to identify small molecule inhibitors. This is aconsolidation of the services Proteros has provided over the past eight yearsin support of Janssen discovery research efforts in the USA and Europe.
Dr. Torsten Neuefeind, CEO ofProteros noted that "it is an important milestone for Proteros that the workperformed by our scientists to support Janssen global discovery research isrecognized as being of such high value that is has developed into thisstrategic collaboration. Proteros looksforward to contributing innovations and high quality science that makes apositive impact on Janssen's research success."
Proteros is a privately held company thatprovides services and proprietary technologies to support integrated drugdiscovery, with an aim to accelerate and improve protein structure analysis andstructure-based drug discovery with its expertise, industrialized processes andunique technologies for crystallography and fragment-based lead generation.Proteros boasts that it complements its clients' internal capabilities with external expertiseand access to flexible resources. Proteros currently provides services for morethan 80 pharmaceutical and biotechnology clients in North America, Europe andAsia.
